Seven Fleet Capital Management LP Cuts Holdings in Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP lessened its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 19.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,723 shares of the company’s stock after selling 16,086 shares during the quarter. Dianthus Therapeutics comprises 1.0% of Seven Fleet Capital Management LP’s portfolio, making the stock its 21st biggest holding. Seven Fleet Capital Management LP’s holdings in Dianthus Therapeutics were worth $6,309,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the last quarter. UBS Group AG increased its stake in Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the period. BNP Paribas Financial Markets raised its stake in shares of Dianthus Therapeutics by 1,275.3% during the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares in the last quarter. SummitTX Capital L.P. lifted its stake in Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after acquiring an additional 12,118 shares during the period. Finally, California State Teachers Retirement System increased its holdings in Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after buying an additional 24,697 shares during the period. Institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush increased their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. HC Wainwright increased their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $126.92.

Insider Activity at Dianthus Therapeutics

In other news, Director Simon Read sold 2,778 shares of the stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total value of $326,553.90. Following the sale, the director directly owned 2,778 shares in the company, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anne McGeorge sold 7,750 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the sale, the director directly owned 1,250 shares in the company, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 283,678 shares of company stock valued at $29,672,400 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $108.10 on Friday. Dianthus Therapeutics, Inc. has a fifty-two week low of $24.49 and a fifty-two week high of $117.88. The stock’s fifty day moving average is $105.23 and its two-hundred day moving average is $89.08. The firm has a market capitalization of $5.91 billion, a P/E ratio of -26.05 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.